Aviano

• A Study of Disitamab Vedotin Alone and with Pembrolizumab in Urothelial Cancer That Expresses HER2 Not authorised
  2022-500030-28-00 4 Urothelial carcinoma
• HARMONi-3 Not authorised
  2023-504989-37-00 5 Metastatic Squamous Non-small Cell Lung Cancer
• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 4 prostate cancer
• A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending
  2024-514701-57-01 4 non Small Cell Lung Cancer
• A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma posit … Pending
  2024-515555-38-01 4 NON SMALL CELL LUNG CANCER
• Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma pat … Pending
  2024-518199-30-00 9 Soft tissue sarcoma patients
• Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial) Pending
  2024-518388-37-00 4 Intermediate risk prostate cancer
• A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III … Pending
  2024-519031-42-00 5 pancreatic ductal adenocarcinoma
• Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with … Pending
  2024-519106-12-00 4 Patients with anaplastic lymphoma kinase positive (ALK+) locally advan
• Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T … Pending
  2024-520093-34-00 5 Acinar cell prostatic carcinoma
• Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending
  2025-520676-26-00 4 Non-small cell lung cancer (NSCLC)
• A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum … Pending
  2025-521209-42-00 6 advanced colorectal cancer with wild-type RAS and right primary tumour
• Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimari … Pending
  2025-521651-22-00 4 hormone receptor positive, HER2-negative breast cancer
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 Pending
  2025-522084-15-00 10 metastatic NSCLC patients
• Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan … Pending
  2025-522167-15-00 5 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L … Pending
  2025-522818-23-00 5 Small Cell Lung Cancer (SCLC)
• A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negativ … Pending
  2025-523460-21-00 4 Metastatic breast cancer
• A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Pending
  2025-523526-40-00 9 Advanced Solid Tumors
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv … Pending
  2025-524048-36-00 5 Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcin
• A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending
  2025-524488-18-00 4 Muscle-invasive Bladder Cancer
• A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending
  2025-525013-23-00 4 Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

Showing 1–24 of 211 trials